Updates are available Erratum dated 2017-03-24
Click to view Erratum: https://doi.org/10.1038/leu.2017.85
-
Authors
Montalban-Bravo, G
Huang, X
Jabbour, E
Borthakur, G
DiNardo, C D
Pemmaraju, N
Cortes, J
Verstovsek, S
Kadia, T
Daver, N
Wierda, W
Alvarado, Y
Konopleva, M
Ravandi, F
Estrov, Z
Jain, N
Alfonso, A
Brandt, M
Sneed, T
Chen, H-C
Yang, H
Bueso-Ramos, C
Pierce, S
Estey, E
Bohannan, Z
Kantarjian, H M
Garcia-Manero, G
- License Information
-
More Information
Article History
Received: 4 July 2016
Revised: 21 August 2016
Accepted: 30 August 2016
First Online: 31 October 2016
Competing interests
: GG-M work has been supported by Celgene, maker of azacitidine, and Merck, maker of vorinostat. Merck supported in part this study. GG-M has served as a consultant and speaker for both Celgene and Merck.
